From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Daflon is a micronized purified flavonoid fraction containing 90% diosmin and 10% other flavonoids expressed as hesperidin. It is manufactured by Laboratoires Servier.[1]

Therapeutic indications[edit]

Daflon is not an FDA-approved medication, meaning that it cannot be advertised for treatment of diseases. However, experimental trials reported it could benefit some people. It is believed daflon is a venotonic (it increases venous tone) and a vasculoprotector (it increases resistance in small blood vessels).[2] It is used experimentally for treating Chronic venous insufficiency and for treating Hemorrhoidal diseases.[3] In an experiment, daflon was found beneficial in the reduction of symptoms after operation for hemorrhoidal disease.[4]

Even though Daflon is not a prescription medication in the US, it is in other countries like France.[5][6] Also diosmiplex, which is also a MPFF (micronized purified flavonoid fraction), with similar venous insufficiency indication, is a prescription medication in the US.[7]

Daflon has undergone recent rabbit experimental trials.[8] There is a Cochrane review concerning Diosmin.[9]


For venous insufficiency, the dosage is 2 tablets daily. For acute hemorrhoidal attack, the dosage is 6 tablets daily for 4 days, followed by 4 tablets daily over the next 3 days.[3]

Side effects[edit]

Possible side effects include routine gastric disorders and neurovegetative disorders.


  1. ^ "Offocial Monograph. Daflon 500: Summary of Product Characteristics" (PDF). www.servier.com.ve. Archived (PDF) from the original on 2016-12-28. Retrieved 2018-12-09.
  2. ^ Lyseng-Williamson KA, Perry CM (2003). "Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids". Drugs. 63 (1): 71–100. doi:10.2165/00003495-200363010-00005. PMID 12487623.
  3. ^ a b "Daflon 500 mg in the management of acute and recurrent hemorrhoidal disease" (PDF). Phlebolymphology: 281–282. Retrieved 10 April 2015.
  4. ^ Astashov, Vladimir L.; Timchenko, Dmitry A. (2014-03-18). "Benefits of micronized purified flavonoid fraction in the reduction of symptoms after operation for hemorrhoidal disease". Phlenolymphology.org. Phlebolymphology. Retrieved 10 April 2015.
  5. ^ "DAFLON - EurekaSanté par VIDAL". EurekaSanté (in French). Retrieved 2018-02-17.
  6. ^ "Notice patient - DAFLON 500 mg, comprimé pelliculé - Base de données publique des médicaments". base-donnees-publique.medicaments.gouv.fr (in French). Retrieved 2018-02-17.
  7. ^ Bush, Ronald; Comerota, Anthony; Meissner, Mark; Raffetto, Joseph D.; Hahn, Steven R.; Freeman, Katherine (April 2017). "Recommendations for the medical management of chronic venous disease: The role of Micronized Purified Flavanoid Fraction (MPFF)". Phlebology. 32 (1_suppl): 3–19. doi:10.1177/0268355517692221. ISSN 1758-1125. PMID 28211296.
  8. ^ de Souza, Maria das Graças C.; Cyrino, Fatima Z. G. A.; Mayall, Monica R.; Virgini-Magalhães, Carlos E.; Sicuro, Fernando L.; de Carvalho, Jorge José; Verbeuren, Tony J.; Bouskela, Eliete (February 2016). "Beneficial effects of the micronized purified flavonoid fraction (MPFF, Daflon® 500 mg) on microvascular damage elicited by sclerotherapy". Phlebology. 31 (1): 50–56. doi:10.1177/0268355514564414. ISSN 1758-1125. PMID 25514922.
  9. ^ Martinez-Zapata, Maria José; Vernooij, Robin W. M.; Uriona Tuma, Sonia Maria; Stein, Airton T.; Moreno, Rosa M.; Vargas, Emilio; Capellà, Dolors; Bonfill Cosp, Xavier (2016-04-06). "Phlebotonics for venous insufficiency". The Cochrane Database of Systematic Reviews. 4: CD003229. doi:10.1002/14651858.CD003229.pub3. ISSN 1469-493X. PMID 27048768.

External links[edit]